Oh Deok Ja, Lee Yoo La, Kang Jae Won, Kwon So Yong, Cho Nam Sun
Blood Transfusion Research Institute, Korean Red Cross, Seoul, Korea.
Korean J Lab Med. 2010 Feb;30(1):58-64. doi: 10.3343/kjlm.2010.30.1.58.
To ensure the safety of plasma derivatives, some countries have been screening for the human parvovirus B19 (B19V) antigen or DNA in blood donors. We investigated the prevalence of B19V DNA and anti-B19V antibodies in Korean plasmapheresis donors to evaluate the necessity of B19V DNA screening test.
Plasma samples were collected between March and July 2008 from 10,032 plasmapheresis donors. The B19V DNA test was performed using the LightCycler 2.0 (Roche, Germany) with quantification kits. Anti-B19V IgM and IgG were tested in 928 randomly selected samples from the 10,032 donors using recomWell Parvovirus B19 ELISA IgM, IgG assay (Mikrogen, Germany). RecomLine Parvovirus B19 LIA IgG, IgM assay (Mikrogen, Germany) was used to analyze the epitopes of antibodies in donors showing positive results for B19V DNA and anti-B19V antibodies. DNA sequencing was performed to identify the genotypes.
The prevalence of B19V DNA was 0.1% (10/10,032). Virus titers in B19V DNA positive donors were less than 10(5) IU/mL (range: 2.7 x 10(1)-3.2 x 10(4) IU/mL) except for 1 donor (1.33 x 10(8) IU/mL). All the isolated B19V DNAs from 6 donors were identified as genotype I. Nine out of 10 B19V DNA positive donors also possessed anti-B19V IgG only or IgG and IgM. The prevalence of anti-B19V IgG was 60.1% (558/928).
The prevalence of B19V DNA in Korean blood donors was not high and most donors also possessed neutralizing anti-B19V antibodies. Thus, the implementation of a B19V screening test for Korean blood donors does not appear to be imperative.
为确保血浆衍生物的安全性，一些国家一直在对献血者进行人细小病毒B19（B19V）抗原或DNA筛查。我们调查了韩国血浆置换献血者中B19V DNA和抗B19V抗体的流行情况，以评估B19V DNA筛查试验的必要性。
2008年3月至7月间从10,032名血浆置换献血者中采集血浆样本。使用罗氏LightCycler 2.0（德国）及定量试剂盒进行B19V DNA检测。使用重组细小病毒B19 ELISA IgM、IgG检测试剂盒（德国Mikrogen公司）对从10,032名献血者中随机选取的928份样本检测抗B19V IgM和IgG。使用重组细小病毒B19 LIA IgG、IgM检测试剂盒（德国Mikrogen公司）分析B19V DNA和抗B19V抗体检测呈阳性的献血者体内抗体的表位。进行DNA测序以鉴定基因型。
B19V DNA的流行率为0.1%（10/10,032）。除1名献血者（1.33×10⁸ IU/mL）外，B19V DNA阳性献血者的病毒滴度均低于10⁵ IU/mL（范围：2.7×10¹ - 3.2×10⁴ IU/mL）。从6名献血者中分离出的所有B19V DNA均鉴定为I型。10名B19V DNA阳性献血者中有9名仅拥有抗B19V IgG或同时拥有IgG和IgM。抗B19V IgG的流行率为60.1%（558/928）。
韩国献血者中B19V DNA的流行率不高，且大多数献血者还拥有中和性抗B19V抗体。因此，对韩国献血者实施B19V筛查试验似乎并非势在必行。
